⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCUL News
Ocular Therapeutix, Inc.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Form 8-K
sec.gov
OCUL
Ocular Therapeutix™ to Participate in March Investor Conferences
globenewswire.com
OCUL
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
globenewswire.com
OCUL
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD
globenewswire.com
OCUL
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
globenewswire.com
OCUL